Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 50008994
Affinity DataIC50: 3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 160nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 260nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 270nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 270nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 350nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 600nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 650nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 700nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 770nMAssay Description:Inhibition of urokinase (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 2.80E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.60E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.70E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.80E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.80E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
Affinity DataIC50: 5.20E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 6.50E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7.70E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 8.09E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 8.20E+3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 8.70E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.36E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+4nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of urokinase (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.20E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+4nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 6.40E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
















